- The FDA grants Fast Track status to Threshold Pharmaceuticals' (THLD +9.1%) TH-302 for the treatment of previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcoma. The product candidate is in Phase 3 development for this indication. The primary analysis of overall survival will be done in Q1 2016.
- Fast Track status allows for more frequent interactions with the FDA and a rolling review of the NDA in order to expedite the approval process.
Threshold Pharma cancer drug candidate Fast Track'd
Recommended For You
About MTEM Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
MTEM | - | - |
Molecular Templates, Inc. |